Eli Lilly and Company (LLY) — Stock Score Summary

Eli Lilly and Company (LLY) has a MoatMap StockRank of 76/100 based on Quality (71/100), Value (18/100), and Momentum (70/100) factor scores. The current signal is BUY. Eli Lilly, a top-tier pharmaceutical company with a strong pipeline and undeniable quality, is already largely priced for its significant growth prospects, lacking an unpriced asymmetric macro tailwind from the specified themes for this fund's criteria.

Eli Lilly and Company is a global pharmaceutical powerhouse that discovers, develops, manufactures, and markets innovative medicines across key therapeutic areas such as diabetes, oncology, immunology, and neuroscience. Its wide competitive moat is built on a robust R&D pipeline, extensive patent protection for its blockbuster drugs, and a well-established global sales and distribution network. Eli Lilly is a leading innovator, recently achieving significant market success in diabetes and obesity treatments.

Key Financial Metrics

Price$1K
Market Cap$949.7B
P/E (TTM)36.23
P/E (Forward)22.99
Price/Book29.25
Return on Equity107.5%
Return on Invested Capital38.4%
Debt/Equity139.01
Gross Margin82.8%
Operating Margin49.4%
Revenue Growth55.5%
Dividend Yield0.7%
Free Cash Flow$9.2B

Eli Lilly and Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Eli Lilly and Company’s (LLY) StockRank?
MoatMap’s StockRank for Eli Lilly and Company (LLY) is 76/100, with a Buy signal. It is a composite of Quality (71), Value (18), and Momentum (70) factor ranks across MoatMap’s 19,000+ stock universe.
Does Eli Lilly and Company have an economic moat?
Eli Lilly and Company (LLY) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Eli Lilly and Company a buy, hold, or sell?
MoatMap’s current signal for Eli Lilly and Company (LLY) is Buy, based on a StockRank of 76/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Eli Lilly and Company in?
Eli Lilly and Company (LLY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).
Browse all ranked stocksLLY deep dive reportAI ChampionsHow we score stocksSense-check another stock